EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials

Usha Chakravarthy, Varun Chaudhary, Srinivas R Sadda, Colin S Tan, Stela Vujosevic, Sascha Fauser, Kara Gibson, Carl Glittenberg, Nancy Holekamp, Ben Lanza, Andreas Maunz, Jeffrey R Willis und 1 weitere

Ophthalmology Science · 2025-09 · 5 (5) · 100798

DOI: 10.1016/j.xops.2025.100798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmology Science, 2025-09. Verfasst von Usha Chakravarthy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Public Health, Queen's University of Belfast, Belfast, UK. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F Hoffmann-La Roche Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare the effect of faricimab, a dual angiopoietin-2 (Ang-2) and VEGF-A inhibitor, with aflibercept on resolution of hyperreflective foci (HRF) in patients with diabetic macular edema (DME).

Design

A post hoc analysis of the randomized, double-masked, noninferiority YOSEMITE/RHINE (NCT03622580/NCT03622593) phase III trials.

Participants

Adults with vision loss due to center-involving DME.

Methods

A deep learning-based algorithm was used to automatically quantify HRF in spectral-domain OCT volume scans from YOSEMITE/RHINE. Study eyes were randomized to faricimab 6.0 mg every 8 weeks (Q8W; n = 519), faricimab 6.0 mg according to a personalized treat-and-extend (T&E)-based regimen (n = 524), and aflibercept 2.0 mg Q8W (n = 502). Hyperreflective foci were defined as hyperreflective objects up to 50 μm in diameter and assessed within the 1.0-mm and 3.0-mm-diameter ETDRS rings and by location within the inner and outer retina. Main Outcome Measures: Hyperreflective foci volume and count at baseline and over time through week 48 in the inner, outer, and total retina, 1-mm and 3-mm diameters; time to absence of HRF at 2 consecutive visits in the inner and outer retina, 1-mm diameter over 48 weeks.

Results

Adjusted mean HRF volumes at week 48 were lower for faricimab Q8W (104.1 picoliter [pL]) and faricimab T&E (110.1 pL) compared with aflibercept (180.3 pL; nominal P < 0.001 for both) in the inner retina, 1-mm diameter. In the inner retina, 3-mm diameter adjusted mean HRF volumes at week 48 were lower for faricimab Q8W (763.9 pL) and faricimab T&E (777.2 pL) compared with aflibercept (1030.6 pL; nominal P < 0.001 for both). Similar results were obtained for volumes in the outer retina and for HRF counts. In the inner retina, 1-mm diameter, the 25th percentile for time to absence of HRF count at 2 consecutive visits was achieved 8 weeks earlier with faricimab Q8W and faricimab T&E versus aflibercept.

Conclusions

Greater HRF reductions were achieved with faricimab versus aflibercept, supporting the therapeutic potential of dual Ang-2/VEGF-A inhibition to suppress disease activity in DME. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

Stichwörter der Autor:innen

Angiopoietin-2Diabetic macular edemaFaricimabHyperreflective fociVEGF

Autor:innen und Institutionen

  • Centre for Public Health, Queen's University of Belfast, Belfast, UK.
  • Department of Surgery, Hamilton Regional Eye Institute, McMaster University, Hamilton, Ontario, Canada.
  • Doheny Eye Institute, Pasadena, California.
  • Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, California.
  • National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
  • Department of Biomedical Surgical and Dental Sciences, University of Milan, Milan, Italy.

Förderung

  • F Hoffmann-La Roche Ltd

Zitieren

APA

Chakravarthy, U., Chaudhary, V., Sadda, S. R., Tan, C. S., Vujosevic, S., Fauser, S., Gibson, K., Glittenberg, C., Holekamp, N., Lanza, B., Maunz, A., Willis, J. R., & Singh, R. P. (2025). Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials. Ophthalmology Science, 5(5), 100798. https://doi.org/10.1016/j.xops.2025.100798

Vancouver

Chakravarthy U, Chaudhary V, Sadda SR, Tan CS, Vujosevic S, Fauser S, et al. Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials. Ophthalmology Science. 2025;5(5):100798. doi:10.1016/j.xops.2025.100798

BibTeX
@article{Chakravarthy2025,
  author = {Chakravarthy, Usha and Chaudhary, Varun and Sadda, Srinivas R and Tan, Colin S and Vujosevic, Stela and Fauser, Sascha and Gibson, Kara and Glittenberg, Carl and Holekamp, Nancy and Lanza, Ben and Maunz, Andreas and Willis, Jeffrey R and Singh, Rishi P},
  title = {Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials},
  journal = {Ophthalmology Science},
  year = {2025},
  volume = {5},
  number = {5},
  pages = {100798},
  doi = {10.1016/j.xops.2025.100798}
}
Kostenlos starten →